What's in Organon and Co's pipeline?

Organon and Co has 152 drugs in our index: 40 marketed, 0 filed, 91 in Phase 3, 15 in Phase 2, 6 in Phase 1.

Which companies overlap with Organon and Co's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, Merck Sharp & Dohme LLC, AstraZeneca, Teva Branded Pharmaceutical Products R&D, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/organon-and-co.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Organon and Co — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Organon and Co pipeline: 40 marketed, 0 filed, 91 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

40 marketed 0 filed 91 Phase 3 15 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Desloratadine 5 mg	Desloratadine 5 mg	marketed
Etoricoxib 90 mg	Etoricoxib 90 mg	marketed
Montelukast chewable tablets	Montelukast chewable tablets	marketed
Losartan (+) amlodipine	Losartan (+) amlodipine	marketed	Angiotensin II receptor blocker + calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)	Cardiovascular
Mometasone furoate dry powder inhaler	Mometasone furoate dry powder inhaler	marketed
Placebo for etoricoxib	Placebo for etoricoxib	marketed
Mometasone Furoate MDI 200 mcg	Mometasone Furoate MDI 200 mcg	marketed
fluticasone nasal spray	fluticasone nasal spray	marketed
recFSH	recFSH	marketed
fluticasone propionate hydrofluoroalkane (HFA)	fluticasone propionate hydrofluoroalkane (HFA)	marketed	Inhaled corticosteroid	Glucocorticoid receptors	Immunology
Ezetimibe + Simvastatin	Ezetimibe + Simvastatin	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)	Cardiovascular
Atorvastatin 80 mg	Atorvastatin 80 mg	marketed

Therapeutic area mix

Cardiovascular · 28
Other · 5
Respiratory / Immunology · 5
Neurology · 4
Contraception / Women's Health · 4
Contraception / Gynecology · 3
Oncology · 3
Immunology / Allergy · 3
Allergy/Immunology · 3
Respiratory · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 13 shared drug classes
Sanofi · 12 shared drug classes
Merck Sharp & Dohme LLC · 10 shared drug classes
AstraZeneca · 9 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 9 shared drug classes
Pfizer · 7 shared drug classes
Bayer · 6 shared drug classes
Novartis · 5 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Organon and Co:

Cite this brief

Drug Landscape (2026). Organon and Co — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/organon-and-co. Accessed 2026-05-16.